Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 114

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 2
Chunk 114
---
 and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.

Biotechnology Selected Financial Data 

 Three-Month Period Ended($ in millions)March 28, 2025March 29, 2024Sales$1,612 $1,524 Operating profit441 325 Depreciation34 42 Amortization of intangible assets213 218 Operating profit as a % of sales27.4 %21.3 %Depreciation as a % of sales2.1 %2.8 %Amortization as a % of sales13.2 %14.3 %

Sales Growth and Core Sales Growth% Change Three-Month Period Ended March 28, 2025 vs. Comparable 2024 PeriodTotal sales growth (GAAP)6.0 %Impact of:Currency exchange rates 1.0 %Core sales growth (non-GAAP)7.0 %

Price increases in the segment contributed 1.0% to sales growth on a year-over-year basis during the three-month period ended March 28, 2025 and are reflected as a component of core sales above.

Total segment sales increased 6.0% during the three-month period.  In the three-month period, the increase in segment sales was led by increased core sales in the bioprocessing business, partially offset by the impact of currency exchange rates.  Total segment core sales increased across most major geographic regions.  Improved demand for consumables was partially offset by lower demand for equipment.  Year-over-year core sales increases in the bioprocessing business were primarily driven by improved consumables demand from large pharmaceutical customers, primarily in North America, Europe and Southeast Asia.  Core sales decreased slightly in China as a result of weaker demand for equipment. Core sales in the discovery and medical business increased year-over-year as core sales growth in the high-growth markets was partially offset by lower core sales in North America.

24

Operating Profit Performance

Operating profit margins increased 610 basis points during the three-month period ended March 28, 2025 as compared to the comparable period of 2024.

First quarter 2025 vs. first quarter 2024 operating